TY - JOUR
T1 - What does the PANSS mean?
AU - Leucht, Stefan
AU - Kane, John M.
AU - Kissling, Werner
AU - Hamann, Johannes
AU - Etschel, Eva
AU - Engel, Rolf R.
N1 - Funding Information:
We are indebted to EliLilly and Sanofi-Synthélabo for the possibility of analyzing individual patient data from their databases. This study was supported by a grant for the Zucker Hillside Hospital Intervention Research Center for Schizophrenia (MH-60575).
PY - 2005/11/15
Y1 - 2005/11/15
N2 - Objective: Despite the frequent use of the Positive and Negative Syndrome Scale (PANSS) for rating the symptoms of schizophrenia, the clinical meaning of its total score and of the cut-offs that are used to define treatment response (e.g. at least 20% or 50% reduction of the baseline score) are as yet unclear. We therefore compared the PANSS with simultaneous ratings of Clinical Global Impressions (CGI). Method: PANSS and CGI ratings at baseline (n = 4091), and after one, two, four and six weeks of treatment taken from a pooled database of seven pivotal, multi-center antipsychotic drug trials on olanzapine or amisulpride in patients with exacerbations of schizophrenia were compared using equipercentile linking. Results: Being considered "mildly ill" according to the CGI approximately corresponded to a PANSS total score of 58, "moderately ill" to a PANSS of 75, "markedly ill" to a PANSS of 95 and severely ill to a PANSS of 116. To be "minimally improved" according to the CGI score was associated with a mean percentage PANSS reduction of 19%, 23%, 26% and 28% at weeks 1, 2, 4 and 6, respectively. The corresponding figures for a CGI rating "much improved" were 40%, 45%, 51% and 53%. Conclusions: The results provide a better framework for understanding the clinical meaning of the PANSS total score in drug trials of schizophrenia patients with acute exacerbations. Such studies may ideally use at least a 50% reduction from baseline cut-off to define response rather than lower thresholds. In treatment resistant populations, however, even a small improvement can be important, so that a 25% cut-off might be appropriate.
AB - Objective: Despite the frequent use of the Positive and Negative Syndrome Scale (PANSS) for rating the symptoms of schizophrenia, the clinical meaning of its total score and of the cut-offs that are used to define treatment response (e.g. at least 20% or 50% reduction of the baseline score) are as yet unclear. We therefore compared the PANSS with simultaneous ratings of Clinical Global Impressions (CGI). Method: PANSS and CGI ratings at baseline (n = 4091), and after one, two, four and six weeks of treatment taken from a pooled database of seven pivotal, multi-center antipsychotic drug trials on olanzapine or amisulpride in patients with exacerbations of schizophrenia were compared using equipercentile linking. Results: Being considered "mildly ill" according to the CGI approximately corresponded to a PANSS total score of 58, "moderately ill" to a PANSS of 75, "markedly ill" to a PANSS of 95 and severely ill to a PANSS of 116. To be "minimally improved" according to the CGI score was associated with a mean percentage PANSS reduction of 19%, 23%, 26% and 28% at weeks 1, 2, 4 and 6, respectively. The corresponding figures for a CGI rating "much improved" were 40%, 45%, 51% and 53%. Conclusions: The results provide a better framework for understanding the clinical meaning of the PANSS total score in drug trials of schizophrenia patients with acute exacerbations. Such studies may ideally use at least a 50% reduction from baseline cut-off to define response rather than lower thresholds. In treatment resistant populations, however, even a small improvement can be important, so that a 25% cut-off might be appropriate.
KW - Clinical Global Impressions Scale
KW - Clinical trials
KW - Positive and Negative Syndrome Scale
KW - Response
KW - Schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=26844455017&partnerID=8YFLogxK
U2 - 10.1016/j.schres.2005.04.008
DO - 10.1016/j.schres.2005.04.008
M3 - Article
C2 - 15982856
AN - SCOPUS:26844455017
SN - 0920-9964
VL - 79
SP - 231
EP - 238
JO - Schizophrenia Research
JF - Schizophrenia Research
IS - 2-3
ER -